Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. - Ahrén,B.; Gomis,R.; Standl,E.; Mills,D.; Schweizer,A. (Diabetes Care, 2004)